Full-Time

Medical Science Liaison

Neuroscience

Posted on 10/3/2025

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

No salary listed

Belfast, UK

Remote

Travel expectations for this role is 70% - 80% with overnight stays.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • Strong current knowledge of the therapeutic area including disease, treatment, NHS structure, patient pathway(s) in the UK.
  • A quick learner, able to assimilate and articulate complex data as relevant to audience.
  • A good listener, with high emotional intelligence, able to explore broad areas of interest and opportunities during HCP interactions.
  • Excellent planning and organisation skills.
  • Confident use of IT equipment for delivery of F2F in person and F2F remote interactions.
  • Clear, structured communication and presentation skills.
  • Engages actively with company IT systems, reporting tools and collaborative working tools to ensure compliant reporting, excellent record-keeping and information sharing.
  • Curious and future facing, wanting to learn more, brings innovation and continuous improvement to the team.
  • Strong inter-personal skills, seeking internal collaboration and teamwork.
  • Demonstrates motivation and takes accountability for own self-learning, development, and performance.
  • Excellent command of spoken and written English.
  • Medicine, Pharmacy or Nursing Degree or Scientific Graduate with a higher qualification e.g., PhD, Pharm D, MSc.
  • Experience of working in the NHS and/or previous MSL Experience.
  • ABPI Code trained.
  • Proficient in Microsoft office platforms.
  • Full clean Driving license.
Responsibilities
  • Build and nurture relationships with healthcare professionals and allied health experts in your therapy area.
  • Lead proactive and reactive scientific discussions across the product lifecycle.
  • Identify opportunities for collaboration in research, education, audits, and advisory roles.
  • Spend time in the field to understand real-world challenges and generate actionable medical insights.
  • Stay ahead of the curve with continuous learning in your disease area and product portfolio.
  • Become the trusted go-to expert for HCPs, delivering clear, non-promotional scientific information.
  • Represent the medical function at UK and international congresses, leading and delivering key activities.
  • Share best practices and insights with local and regional medical teams.
  • Collaborate compliantly with commercial teams to align on strategic goals.
  • Drive internal coordination for congress planning, safety reporting, and project execution.
  • Support research initiatives, including medical grants, RWE proposals, and clinical trial site engagement.
  • Develop and deliver internal training on disease area and current and/or emerging treatments.
  • Contribute to annual medical and brand plans, research strategies, and launch activities.
  • Support country-level medical projects, including education and data generation initiatives.
  • Develop and manage MSL territory plans aligned with therapeutic area strategies and HCP needs.
  • Collaborate with commercial teams to deliver coordinated, patient-centric field activities.
Desired Qualifications
  • Experience as an expert speaker or as a trainer.
  • Experience or knowledge of clinical trials operations.
  • ICH-GCP training.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Epidiolex generated $1.1B in 2025 sales, up 9% YoY, with patents protected to late 2030s.
  • Q1 2026 revenue hit $1.1B, up 19% YoY, prompting Raymond James target raise to $239 on May 7.
  • Chimerix acquisition adds dordaviprone for H3 K27M-mutant glioma, PDUFA August 18, 2025.

What critics are saying

  • Generic competition erodes Xywav revenue as it replaces Xyrem, decelerating growth to 5.5% annually.
  • Dordaviprone fails FDA approval on August 18, 2025 PDUFA, wasting $935M Chimerix acquisition.
  • $850M exchangeable notes due 2030 dilute equity at $153.05 exchange price amid EPS decline.

What makes Jazz Pharmaceuticals unique

  • Jazz Pharmaceuticals focuses on neuroscience and oncology for rare diseases with limited treatments.
  • Xywav offers 92% less sodium than Xyrem, approved July 21, 2020, for narcolepsy in patients aged 7+.
  • Epidiolex, acquired via $7.2B GW Pharma deal in 2021, treats Lennox-Gastaut and Dravet syndromes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE